Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D HART

Showing results (611-620 of 623) with videos related to

Pageof 63
Sort By:
The Lancet Regional Health. Western Pacific|February 15, 2024
Immunogenicity, safety, and reactogenicity of a half- versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trialTsetsegsaikhan Batmunkh, Kerryn A Moore, Helen Thomson, et al.
Frontiers in Immunology|April 8, 2026
Fractional BNT162b2 boosters induce durable immune responses after non-mRNA priming in Mongolia: a randomised controlled trialTsetsegsaikhan Batmunkh, Eleanor Fg Neal, Otgonjargal Amraa, et al.
Nature Communications|September 29, 2025
Immunogenicity of fractional and standard dose COVID-19 vaccine boosters among healthy adults in Indonesia: twenty four month follow-up from a randomised controlled trialJohn D Hart, Eddy Fadlyana, Nadia Mazarakis, et al.
Lancet (London, England)|May 6, 2008
Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association studyJ B Richards, F Rivadeneira, M Inouye, et al.
The New England Journal of Medicine|May 15, 2009
Adjuvant chemotherapy in older women with early-stage breast cancerHyman B Muss, Donald A Berry, Constance T Cirrincione, et al.
Cancers|April 13, 2024
Optimising Patient Outcomes in Tongue Cancer: A Multidisciplinary ApproachJasper de Boer, Rebecca Barnett, Anthony Cardin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2019
Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 TrialHyman B Muss, Mei-Yin C Polley, Donald A Berry, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|January 16, 2024
Cost-utility analysis of molnupiravir for high-risk, community-based adults with COVID-19: an economic evaluation of the PANORAMIC trialMay Ee Png, Victoria Harris, Jenna Grabey, et al.
Lancet Regional Health. Americas|February 13, 2023
Validation of SmartVA using conventional autopsy: A study of adult deaths in BrazilJohn D Hart, Paulo Afonso de André, Carmen Diva Saldiva de André, et al.
The Lancet. Infectious Diseases|September 12, 2024
Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trialVictoria Harris, Jane Holmes, Oghenekome Gbinigie-Thompson, et al.
Pageof 63

Showing results (611-620 of 623) with videos related to

Sort By:
Pageof 63
The Lancet Regional Health. Western Pacific|February 15, 2024
Immunogenicity, safety, and reactogenicity of a half- versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trialTsetsegsaikhan Batmunkh, Kerryn A Moore, Helen Thomson, et al.
Frontiers in Immunology|April 8, 2026
Fractional BNT162b2 boosters induce durable immune responses after non-mRNA priming in Mongolia: a randomised controlled trialTsetsegsaikhan Batmunkh, Eleanor Fg Neal, Otgonjargal Amraa, et al.
Nature Communications|September 29, 2025
Immunogenicity of fractional and standard dose COVID-19 vaccine boosters among healthy adults in Indonesia: twenty four month follow-up from a randomised controlled trialJohn D Hart, Eddy Fadlyana, Nadia Mazarakis, et al.
Lancet (London, England)|May 6, 2008
Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association studyJ B Richards, F Rivadeneira, M Inouye, et al.
The New England Journal of Medicine|May 15, 2009
Adjuvant chemotherapy in older women with early-stage breast cancerHyman B Muss, Donald A Berry, Constance T Cirrincione, et al.
Cancers|April 13, 2024
Optimising Patient Outcomes in Tongue Cancer: A Multidisciplinary ApproachJasper de Boer, Rebecca Barnett, Anthony Cardin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2019
Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 TrialHyman B Muss, Mei-Yin C Polley, Donald A Berry, et al.
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|January 16, 2024
Cost-utility analysis of molnupiravir for high-risk, community-based adults with COVID-19: an economic evaluation of the PANORAMIC trialMay Ee Png, Victoria Harris, Jenna Grabey, et al.
Lancet Regional Health. Americas|February 13, 2023
Validation of SmartVA using conventional autopsy: A study of adult deaths in BrazilJohn D Hart, Paulo Afonso de André, Carmen Diva Saldiva de André, et al.
The Lancet. Infectious Diseases|September 12, 2024
Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trialVictoria Harris, Jane Holmes, Oghenekome Gbinigie-Thompson, et al.
Pageof 63